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Purpose To assess and compare sexual function in pituitary adenoma patients treated with 
or without postoperative radiation therapy (RT) and with or without testosterone substitution 
therapy.
Methods and Materials This cross-sectional study included 166 pituitary adenoma patients 
(90 men and 76 women, aged 59 ± 11 years) treated between 1962 and 2010 at the University 
Medical Center Groningen. RT was administered in 93 (56%) patients. Sexual function was 
assessed by the Female Sexual Function Index (FSFI) or International Index of Erectile 
Function (IIEF) standardized questionnaires. 
Results In none of the domains of sexual functioning scores, significant differences were 
found between patients (female or male) treated with or without postoperative RT and 
between male patients treated with or without testosterone substitution therapy. In female 
patients, a FSFI total score of 26.55 or less (i.e. sexual dysfunction) was observed in 44/58 
(76%) of patients and similar results were found in postoperative RT patients compared to 
surgery alone patients (log-rank test RR 0.94, 95% CI 1.73-0.51, p = 0.85). In male patients, 
erectile function score of 25 or less (i.e. erectile dysfunction) was observed in 53/89 (60%) of 
patients and was similar between patients treated with postoperative RT and surgery alone 
(log-rank test RR 1.06, 95% CI 0.60-1.85, p = 0.83) and between patients treated with or 
without testosterone substitution therapy (log-rank test RR 1.27, 95% CI 0.65-2.46, p = 0.49).
Conclusions Postoperative radiation therapy and testosterone substitution therapy were not 












































In pituitary adenoma patients postoperative (RT) results in local tumor control rates of 90-
97% at 10 years [1-4] and in an improvement of excessive hormonal secretion in 60-76% 
of acromegaly patients and in 80-85% of Cushing’s disease patients at 10 years [5-8]. 
However, pituitary adenomas are benign tumors, and the safety of RT has been debated, 
in particular because of concerns related to possible long-term side effects. The most 
important and frequent long-term side effect of pituitary RT is hypopituitarism. In patients with 
a normal pituitary function before the start of RT, hormonal replacement therapy with, thyroid 
hormones, glucocorticoids or sex hormones is required in 15-27% of patients at 10 years after 
RT treatment [4,7].
Several hormones regulate directly or indirectly all domains of human sexual functions (i.e. 
desire, erection/lubrication, orgasm and ejaculation) [9]. Consequently, endocrine disease can 
disturb sexual functions, and sexual dysfunction may signal an underlying endocrine disease, 
such as pituitary adenoma [10]. Sexual dysfunction is also common in patients with chronic 
diseases [11]. Moreover, sexual dysfunction can occur as a result of the disease itself or as 
side-effect of the treatment(s) [12] and is associated with reduced quality of life [11]. 
Sexual function is still a poorly studied aspect of quality of life in pituitary adenoma 
patients. The pituitary disease itself and treatment(s) (i.e. surgery and/or postoperative RT) 
can result in hypopituitarism and, more specifically, in sex hormone deficiencies. However, 
limited data are available on the long-term side effects of RT and its associated pituitary (sex) 
hormone deficiencies on sexual function in pituitary adenoma patients, and about the effects 
of sex-hormone substitution therapy. In the light of our earlier results on the effects of RT, we 
postulated that RT has no additional effect on sexual function in pituitary adenoma patients 
treated with surgery. Therefore, we assessed and compared sexual function in pituitary 
adenoma patients treated with or without RT and sex hormone substitution therapy.
METHODS AND MATERIALS
Patients
The inclusion criteria for this cross-sectional study were: age ≥ 18 years, treatment for pituitary 
adenoma (i.e., non-functioning adenoma (NFA), growth hormone (GH) secreting adenoma or 
adrenocorticotropic hormone (ACTH) secreting adenoma), an interval between last treatment 
(surgery or postoperative RT, or initiation of hormone substitution therapy) and questionnaire 
assessment of at least 12 months to assure that acute post-treatment effects had resolved, and 
sufficient knowledge of the Dutch language. All patients included in this study were treated with 
surgery as primary treatment at the University Medical Center Groningen (UMCG). Indications 










































in case of residual disease after resection and medical treatment, or as salvage treatment in 
patients with recurrent disease after surgery. The pituitary adenoma patients were identified 
from a hospital database of two previously reported pituitary adenoma cohort studies [13,14]. 
Patients were only recruited for participation if they were still actively followed at our hospital 
to assure an accurate and complete data collection, and by providing the opportunity for 
the recruited patient to discuss the study with their own treating endocrinologist or radiation 
oncologist. Ultimately, a total of 268 eligible patients (NFA n = 143, GH-secreting adenoma 
n = 93, ACTH-secreting adenoma n = 32, including Cushing’s disease n = 28 and Nelson’s 
syndrome n = 4) were identified who all received surgical treatment in our hospital between 
January 1962 and March 2008. 
Eligible patients received an announcement and information letter concerning the study 
followed by a package including a sexual function questionnaire. After two weeks, reminder 
letters of the study were sent to all patients by mail. Patients were classified as non-responders 
if they actively declined to participate or if they could not be reached after one reminder 
attempt. Approval of the study was given by the medical ethics review committee of the UMCG 
and written informed consent was obtained from all patients.
Sexual function questionnaires
A demographic and health-related data questionnaire was used with special attention for 
educational level, social status, employment status, social security benefit, co-morbidity, 
current medication, marital status and sexual orientation. 
Female Sexual Function Index. The Female Sexual Function Index (FSFI) questionnaire 
contains 19 items and is a validated, brief multidimensional scale for assessing sexual function 
in women [15]. The FSFI includes 6 domains of sexual function (desire, arousal, lubrication, 
orgasm, satisfaction and pain). Higher scores represent better sexual functioning. The FSFI 
total score (sum of all domains) has a minimum score of 2 and a maximum score of 36. A FSFI 
total score below 26.55 indicates sexual dysfunction [16,17]. 
International Index of Erectile Function. The International Index of Erectile Functioning 
(IIEF) questionnaire consists of 15 items and is a widely used, validated, multi-dimensional 
self-report instrument for the evaluation of male sexual function [18]. The IIEF measures 
5 domains of sexual function in men (sexual desire, erectile function, orgasmic function, 
intercourse satisfaction, overall satisfaction) and provides a total score (sum of all domains) 
with a minimum and maximum of 5 and 75, respectively. A higher score indicates better sexual 
function. The erectile function domain consists of 6 items with a minimum score of 1 and a 












































Sex hormone substitution therapy
Sex hormone substitution therapy and sexual function were only assessed and compared 
in male pituitary adenoma patients treated with or without testosterone substitution therapy. 
In post-menopausal female patients (i.e. > 50 years) sex hormone substitution therapy 
is not indicated. In our study the median age of the female patient responders with partner 
was 57 years (range 23-82) and only 10 patients received sex hormone substitution therapy 
(median age 46 years, range 23-72). Therefore, sex hormone substitution therapy was not 
assessed and compared in female patients. 
Statistical analysis
The clinical characteristics of the patients are presented as absolute numbers, median (range), 
or number (percentage). Categorical variables were analyzed using chi-square test (χ2 test) 
and continuous variables were analyzed by the Mann-Whitney U test. Preliminary analyses of 
the data demonstrated a partner and age effect on all sexual function domain score outcomes 
in women and men (data not shown). Therefore, in the sexual function score analyses, we 
chose to report outcomes of patients with a partner (N = 166) and excluded the patients 
without a partner (N = 15). Further consideration of the sexual function scores data of all 
patients (RT and surgery-alone) with partner showed not normal distributed values consisting 
of almost maximum scores in all the domains of sexual function at a young age (e.g. 20 to 40 
years), followed by a slowly progressive decline in sexual function score with increasing age 
(e.g. 40 to 70 years), subsequently followed by a fast progressive decline in sexual function 
score at more advancing age (e.g. > 70 years), and finally resulting in minimum scores in all 
sexual function domains at an old age (e.g. 80 to 90 years). Figure 1 illustrates this course 
of the sexual function scores data over the age with an example of the age at decreasing 
erectile function scores in males. The median age at decreasing erectile function scores of 
< 30, < 25, < 20 and < 15 for example, is respectively 63, 68, 69 and 70 years. Figure 1 also 
illustrates that the sexual function scores data are non-normally distributed and that there is 
a non-lineair relationship with age and sexual function scores, and therefore, multivariable 
lineair regression analysis cannot be performed. For optimal assessment of differences in 
sexual function scores, taking the complex data distribution over the age into consideration, 
we decided to use “below half the maximum sexual function scores”. In this way the largest 
differences in sexual function scores over the age are to be expected because the half below 










































Figure 1 Age at decreasing erectile function scores in male pituitary adenoma patients. 
 
Age at erectile function score < 30 in pituitary adenoma patients. 
Age at erectile function score < 25 in pituitary adenoma patients. 
Age at erectile function score < 20 in pituitary adenoma patients. 
Age at erectile function score < 15 in pituitary adenoma patients. 
Age at erectile function score < 10 in pituitary adenoma patients. 
Age at erectile function score < 5  in pituitary adenoma patients. 
Age at erectile function score 1 in pituitary adenoma patients. 
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In Figure 1 this is illustrated by a fast progressive decline in erectile function scores at an 
age of > 70 years by the narrowing of the erectile function scores lines representing the 
different erectile function scores. The Kaplan-Meier method was used and statistics by the 
log-rank test to analyze the prevalence of all sexual function domains scores using below half 
of the maximum scores with age as the time scale and to analyze the prevalence of sexual 
dysfunction in women (i.e. FSFI total score ≤ 26.55) or ED (i.e. IIEF erectile function score 
≤ 25) between patients (RT versus surgery alone and testosterone versus no testosterone 
substitution therapy). In this way, any effects of age on sexual function scores are corrected 
by the log-rank test and all patients of all ages are included in the analyses and compared to 
patients of the same age. Statistics by the log-rank test was used with which the number of 
observed events and the calculated expected values (i.e. extent of exposure) were used to 
calculate relative risks (RRs). 
All statistical tests were 2-sided, with a P value < .05 regarded as statistically significant. 
SPSS (Statistical Package for the Social Sciences, IBM, Armunk, NY, USA) version 22 and 
Excel version 2013 was used for data analysis.
RESULTS
Patient characteristics
One hundred and eighty-one patients (98 men and 83 women, aged 58 ± 11 years) returned 
all questionnaires (response rate: 68%). Of the responders, a total of 76 female (91.6%) 
and 90 male (91.8%) patients reported to have a partner (N = 166) and were included in 
the sexual function analyses. The clinical characteristics of the female and male patients 
with partner treated with or without RT are shown in Table 1 and 2. Significant differences 
in clinical characteristics were present between patients treated with and without RT (Table 
1 and 2), most importantly, RT patients had a significantly longer follow-up duration, more 
often a craniotomy, an incomplete resection, and hormonal substitution therapy, and less often 
hormone excess control compared to surgery alone patients. In addition, female RT patients 
had a significantly younger age at diagnosis, less often an ACTH-secreting adenoma diagnosis 
and more often a second surgical treatment compared to surgery alone patients. However, 
social status, educational level, employment status, social security benefit, nationality, marital 
status, length of relationship, age of the partner and the number of patients with no other co-
morbidities were all similar between both treatment groups (data not shown). Medication use 
was significantly more often reported in RT patients compared to surgery-alone patients. All 
participating patients reported to be heterosexual. 
All irradiated patients in this study were treated with external beam RT with 4- to 18-MeV 
photons from 1978 to 2010. The median total and fraction radiation dose were 45 Gy (range 















































Age at questionnaire assessment (y)














Control of hormone excess
(GH- and ACTH-secreting adenoma)
Postoperative RT
Age at RT (y)
Time between 1st surgery and RT (y)
Hormonal substitution






































































Abbreviations: ACTH = adrenocorticotropic hormone; GH = growth hormone; RT+ = patients with 
postoperative radiation therapy; RT- = patients with surgery alone; NS = non-significant; y: year.











































Table 2. Clinical characteristics of the male pituitary adenoma patients treated with or without 
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Sexual function in female patients treated with or without RT
The observed and expected numbers and RRs for the prevalence of all sexual function 
domains below half maximum scores in female patients treated with and without postoperative 
RT is presented in Table 3. There were no significant differences in all domains of sexual 
function scores between patients treated with or without RT (Table 3). Fig. 2 illustrates the age 
below half maximum scores of the total FSFI sexual function score domain (i.e. FSFI score 
< 18) in all patients. Furthermore, a FSFI total score of 26.55 or less (i.e. sexual dysfunction) 
was observed in 44/58 (76%) of patients and was similar in RT patients compared to surgery 
alone patients (log-rank test RR 0.94, 95% CI 1.73-0.51, p = 0.85) (Fig. 2). 
Table 3. The prevalence of all sexual function below half maximum scores in female (FSFI) and male 
(IIEF) pituitary adenoma patients treated with and without postoperative radiation therapy.
  RT+
 Obs Exp 
  RT- 
 Obs Exp   
 RR 95% CI    P*
FSFI 
Sexual desire (< 3) 
Sexual arousal (< 3)
Lubrication (< 3)
Orgasm (< 3)
Sexual satisfaction (< 3)
Pain (< 3)
Total score (< 18)
IIEF
Sexual desire (< 5)
Erectile function (< 15)
Orgasmic function (< 5)
Intercourse satisfaction (< 8)
Overall satisfaction (< 5)
Total score (< 38)
   31   26.7
   27   22.6
   25    21
   27    22.0
   12    11.5
   21    20.0
   17    15.4
   14    13.8
   28    26.4
   25    22.2
   29    28.2
   12    13.8
   29    27.6
   18    22.3 
   14    18.4
   14    18 
   13    18
     6      6.5
   14    15.0
     8      9.6
     8      8.2
   15    16.6
     7      9.8
   17    17.8
     9      7.2



























       0.22
       0.17
       0.20
       0.11
       0.82
       0.74
       0.51
       0.92
       0.62
       0.28
       0.80
       0.42
       0.64
Abbreviations: IIEF: International Index of Erectile Function; FSFI: Female Sexual Function Index; 
Obs: observed; Exp: expected; RR: relative risk; CI: confidence interval; P*: univariate analysis. Other 











































Figure 2 Age at sexual dysfunction and the age below half maximum total scores in female 
pituitary adenoma patients treated with and without postoperative radiation therapy. 
 
Age at sexual dysfunction (i.e. total score ≤ 26.55) in female patients treated with 
postoperative radiation therapy. 
Age at sexual dysfunction (i.e. total score ≤ 26.55) in female patients treated 
without postoperative radiation therapy. 
Age at half below maximum total score (i.e. total score < 18) in female patients 
treated with postoperative radiation therapy. 
Age at half below maximum total score (i.e. total score < 18) in female patients 
treated without postoperative radiation therapy. 
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Sexual function in male patients treated with or without RT 
The observed and expected numbers and RRs for the prevalence of all sexual function 
domains below half maximum scores in male patients treated with and without postoperative 
RT is presented in Table 3. There were no significant differences in neither domains of sexual 
function scores between patients treated with or without RT (Table 3). Fig. 3 illustrates the 
age below half maximum erectile function domain scores (i.e. IIEF score < 15) in all patients. 
Furthermore, erectile function domain scores of 25 or less (i.e. erectile dysfunction) was 
observed in 53/89 (60%) of patients and were similar between patients treated with RT and 
surgery alone (log-rank test RR 1.06, 95% CI 0.60-1.85, p = 0.83) (Fig. 3). 
Sexual function in male patients treated with or without testosterone substitution therapy
The observed and expected numbers and RRs for the prevalence of sexual function below half 
maximum scores in male pituitary adenoma patients treated with and without sex hormone 
substitution therapy is presented in Table 4. There were no significant differences in neither 
domains of sexual function scores between male patients treated with or without testosterone 
substitution therapy. Erectile function domain scores of 25 (i.e. erectile dysfunction) or less 
were similar between patients treated with and without testosterone substitution therapy (log-
rank test RR 1.27, 95% CI 0.65-2.46, p = 0.49).
Table 4. The prevalence of sexual function below half maximum scores in male pituitary adenoma 
patients treated with and without sex hormone substitution therapy. 
 SUBST+
Obs   Exp
 SUBST-
Obs   Exp
 RR 95% CI           P*
IIEF
Sexual desire (< 5)
Erectile function (< 15)
Orgasmic function (< 5)
Intercourse satisfaction (< 8)
Overall satisfaction (< 5)
Total score (< 38)
  16    16.1
  33    31.6
  26    23.9
  34    33.7
  16    16.6
  33    32.6
    6      5.9 
  10    11.4
    6      8.1
  12    12.3
    5      4.4













       0.95
       0.63
       0.39
       0.92
       0.74
       0.87
Abbreviations: SUBST+: male patients with sex hormone substitution therapy; SUBST-: male patients 











































Figure 3 Age at erectile dysfunction and the age below half maximum erectile function 




Age at erectile dysfunction (i.e. erectile function score ≤ 25) in male patients 
treated with postoperative radiation therapy. 
Age at erectile dysfunction (i.e. erectile function score ≤ 25) in male patients 
treated without postoperative radiation therapy. 
Age at below half maximum erectile function scores (i.e. erectile function 
score < 15)  in male patients treated with postoperative radiation therapy. 
Age at below half maximum erectile function scores (i.e. erectile function 
score < 15) in male patients treated without postoperative radiation therapy.
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In this study we showed that postoperative RT and testosterone substitution therapy were not 
associated with an impaired sexual function in pituitary adenoma patients.
Sexual function was measured with the FSFI and IIEF questionnaires. The FSFI and IIEF 
are brief, internationally widely used, and reliable self-administered questionnaires that are 
culturally, linguistically and psychometrically valid measures of sexual function in women and 
erectile function in men [15,18]. Furthermore, the FSFI has excellent discriminant validity to 
predict the presence or absence of sexual complaints in women and the erectile function 
domain of the IIEF has been shown to be a valid diagnostic tool for distinguishing men with 
and without erectile dysfunction [15,17,19]. 
To our knowledge, this is the first study investigating the long-term side effects of 
postoperative RT and surgery alone on several domains of sexual function in pituitary adenoma 
patients. Furthermore, the effects of testosterone substitution therapy on sexual function in 
male patients were compared to patients who did not need testosterone substitution therapy 
as a reference group. In this study, we compared the sexual function with patients of the 
same age. Several studies reported on age-associated increases in sexual dysfunction with 
advancing age [20,21] and because age may differ between treatment groups, sexual function 
of patients of the same age should be compared. 
Quality of life is impaired in pituitary adenoma patients compared with the general 
population [22]. Furthermore, sexual dysfunction is associated with a reduced quality of life 
[11]. Sexual dysfunction may occur as a result of pituitary (sex) hormone deficiencies and 
sexual function may provide an integrated and sensitive measure of hormonal dysfunction 
and chronic disease. However, sexual function is a poorly studied aspect of quality of life 
in pituitary adenoma patients. In a study by van Aken et al. the presence of one or multiple 
pituitary hormone deficiencies requiring hormone substitution therapy was an important 
independent predictor for decreased quality of life [23]. In patients with pituitary hormone 
deficiencies, the intrinsic imperfections of hormonal substitution therapy in mimicking the 
normal hormonal secretion may result in subtle physiological derangements [24,25] and this 
may result in decreased quality of life and in an impaired sexual function. Postoperative RT 
can result in hypopituitarism and, more specifically, in sex hormone deficiencies. However, in 
this study, postoperative RT and testosterone substitution therapy were not associated with 
an impairment in sexual function. These results may suggest that patients with hormonal 
substitution therapy are adequately substituted and that subtle physiological derangements 
do not negatively affect the sexual function. Furthermore, several other studies have shown 
that postoperative RT is not associated with reduced quality of life in pituitary adenoma 
patients [26-28]. In addition, we found that prolonged treatment for biochemical control of 











































pituitary adenoma patients treated with or without RT and testosterone substitution therapy 
cannot be compared to other studies because there are currently, to our knowledge, no similar 
studies available in the literature. However, sexual dysfunction is common in patients with 
chronic diseases and mechanism of interference may be neurological, vascular, hormonal, 
musculoskeletal, or psychological [11,12].
In this present study several limitations need to be addressed. First, this is a cross-
sectional study. Sexual function questionnaires were used to measure sexual function at one 
time-point after pituitary adenoma diagnosis and treatment to investigate the associations of 
long-term treatment effects (as potential risk factors) and sexual function. Therefore, the study 
does not provide any information on sexual function before pituitary adenoma diagnosis or 
during the treatments, and the effects of differences in follow-up duration on sexual function 
are unknown. Second, the FSFI and IIEF questionnaires only assess current sexual function, 
while the etiology of sexual dysfunction is not addressed. In addition, these questionnaires 
provide limited assessment of the partner relationship, and they do not assess the level 
of distress associated with the reported sexual dysfunction. Third, pituitary sex hormone 
deficiencies in male patients were identified by the use of testosterone substitution therapy. 
The testosterone hormone levels and the use of different testosterone treatment options were 
unknown, so this study was unable to address this point more specifically. Lastly, a reference 
population was not included in the current study. 
Health care professionals are often hesitating to inquire about sexual function in patients 
with chronic diseases [12]. In our study, the high response rate of 68% of our patients may 
reflect the importance of sexual function to our patients. The quality of patient care may improve 
by giving attention to sexual function during consultations and follow-up in the endocrinology 
out-patient clinic and by referring patients with sexual problems to a gynaecologist, urologist 
or sexuologist for proper evaluation and counseling.
In conclusion, our study revealed no significant differences in sexual function between 
pituitary adenoma patients treated with postoperative RT and surgery alone. In addition, 
testosterone substitution therapy was not associated with an impaired sexual function.
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